- ImmunoGen is a biotechnology company that develops antibody-drug conjugates (ADCs) for cancer treatment.
- Its drug Elahere proved statistically significant and clinically meaningful improvements in progression-free survival (PFS) of ovarian cancer patients versus chemotherapy in its phase 3 MIRASOL late-stage study.
- ImmunoGen shares rocketed over 130%, enabling it to price a $325 million secondary offering comprised of 26 million shares at $12.50 per share led by Goldman Sachs.
- Proceeds will be used for working capital and allocated towards more commercialization for Elahere.
- ImmunoGen awaits full U.S. FDA approval and European approval.
- 5 stocks we like better than ImmunoGen
Commercial-state biotechnology company ImmunoGen Inc. NASDAQ: IMGN shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug Elahere shows statistical improvements for progression-free survival (PFS) and overall survival (OS) for patients in a MIRASOL late-stage study.
The PFS is the length of time a cancer patient lives during and after treatment without worsening the disease. Elahere had shown a clinically meaningful and statistically significant improvement in PFS compared to chemotherapy. The news sent shares skyrocketing over 140% in the week, enabling the company to make a $325 million secondary stock offering of 26 million shares at $12.50 per share.
Platinum-Resistant Ovarian Cancer
This type of ovarian cancer doesn't respond well to platinum-based chemotherapy drugs like cisplatin and carboplatin, which are standard initial treatments. Many patients develop a resistance to these, which makes treating them even more difficult. The treatment often shows initial success, but the cancer recurs or progresses further after treatment.
Antibody-Drug Conjugates (ADCs)
ADCs are designed to selectively and specifically target and deliver anti-cancer drugs to tumor cells and stay away from healthy cells. It uses antibodies that bind to specific antigens found on the surface of target cancer cells. Once it binds, it releases potent anti-cancer agents as a "payload" to kill the cell.
Elahere or mirvetuximab soravtansine-gynx is described by ImmunoGen as a "first-in-class ADC targeting folate receptor alpha (Fra). Fra is a protein found on the cell surface of epithelial tumors, including ovarian, endometrial and non-small cell lung cancers.
ImmunoGen competes with Pfizer Inc. NYSE: PFE acquired Seagen Inc. NASDAQ: SGEN, a leader in ADC treatments as well as ovarian cancer treatments from AstraZeneca Plc NASDAQ: AZN and GSK plc NYSE: GSK
Elahere MIRASOL Study Results
The MIRASOL clinical trial consisted of 453 patients with platinum-resistance ovarian cancer with high levels of Fra. Of the patients, 62% had received prior treatment with bevacizumab. The study's primary endpoint was PFS, and secondary endpoints included objective response rate (ORR) and OS.
Compared to investigators' choice (IC) chemotherapy, Elahere significantly improved OS indicating a 33% reduction in risk of death and PFS, indicating a 35% reduction in tumor progression. The median OS was 16.46 months versus 12.75 for chemotherapy. Median PFS was 5.62 months compared to 3.98 months for chemotherapy. The ORR for Elahere was 32.4% compared to 15.9% for the IC chemotherapy group. The safety profile was favorable, with no new safety issues other than the low-grade ocular and gastrointestinal events.
Elahere or was already granted an accelerated FDA approval for adult patients suffering from Fra-positive platinum-resistance cancer in the fallopian tube, ovarian or primary peritoneal regions after having undergone up to three systemic treatment regimens. The positive late-stage phase 3 trial results were a victory overturning its earlier phase 3 trials that showed no significance over chemotherapy.
While the data is positive, FDA approval is never a sure thing. ImmunoGen is awaiting full FDA approval as well as European approval. If approved, the company will still need physicians and patients to consider using the drug versus conventional treatments for platinum-resistant ovarian cancer. It will also need to be accepted by Medicare and health insurers for reimbursements.
On May 3, 2023, Piper Sandler upgraded shares of IMGN from Neutral to Overweight, raising the price target from $6 to $16. ImmunoGen analyst ratings and price targets can be found on MarketBeat.
Weekly Symmetrical Triangle Breakout
IMGN weekly candlestick chart illustrates a symmetrical triangle breakout through the weekly market structure low (MSL) trigger at $5.56. A symmetrical triangle comprises lower highs on bounces and higher lows on a pullback as the range gets tighter until the upper falling trendline or lower rising trendline breaks. In this case, the upper trendline breakout occurred on heavy volume. Shares spiked as high as $14.00 after the phase 3 trial results announcement.
Remember that the secondary offering for 26 million shares is priced at $12.50, which should provide an initial floor for the stock price. However, if that level breaks, then be aware of the pullback support levels, which are $10.88 previous swing high, $8.75, $7.76 and $5.56 weekly MSL trigger.
Before you consider ImmunoGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunoGen wasn't on the list.
While ImmunoGen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report